Phaseline

Companies › Incannex Healthcare

Incannex Healthcare: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IHL-42X
Dronabinol (cannabinoid CB1/CB2 receptor agonist) combined with acetazolamide (carbonic an
CNR1, CNR2, CA2Phase 2Obstructive Sleep Apnea (OSA)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07635563IHL-42XPhase 2Obstructive Sleep Apnea (OSA)RespiratoryApr 2027

From the company's SEC filings

Cash of $68m on 2026-06-30; operating cash outflow about $13m a year; runway about 63 months at that burn, to Sep 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

CNR1 (1) CNR2 (1) CA2 (1)

Companies with the same targets

IGC Pharma Zynerba Pharmaceuticals Bazelet Nehushtan Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

Contineum Therapeutics Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.